About Curtis Rhine
Form D filings for RS BioTherapeutics from 2023 to 2024 list Curtis Rhine as chief financial officer.
Curtis Rhine first appears on SEC filings in 2023.
Experience
This experience comes from SEC filings. The years are when the filings name Curtis Rhine in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Curtis Rhine works with at each company, as listed on that company's latest Form D.
RS BioTherapeutics Inc. · Form D, Oct 9, 2024
MG
Michael Guzman
Executive officer
HH
H. Hart
Executive officer
JM
Justin Molignoni
Executive officer and director
DF
David Freas
Director